Development of a novel class of interleukin-2 immunotherapies for metastatic cancer
Tumour immunotherapy, and particularly immue checkpoint inhibitors, have resulted in considerable response rates in patients with metastatic cancer. However, most of these approaches are limited to immunogenic tumours. Based on its ability to stimulate cytotoxic T cells, interleukin-2 (IL-2) has b...
Main Authors: | Onur Boyman, Natalia Arenas-Ramirez |
---|---|
Format: | Article |
Language: | English |
Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2019-01-01
|
Series: | Swiss Medical Weekly |
Subjects: | |
Online Access: | https://www.smw.ch/index.php/smw/article/view/2564 |
Similar Items
-
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseasesResearch in context
by: Miro E. Raeber, et al.
Published: (2023-04-01) -
The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
by: Howard L. Kaufman, et al.
Published: (2014-03-01) -
Rethinking Oncologic Treatment Strategies with Interleukin-2
by: Brian Ko, et al.
Published: (2023-05-01) -
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies
by: Grace Lui, et al.
Published: (2023-06-01) -
The application of Interleukin-2 family cytokines in tumor immunotherapy research
by: Yangyihua Zhou, et al.
Published: (2023-03-01)